Individualized dosing of fluoropyrimidine‐based chemotherapy to prevent severe fluoropyrimidine‐related toxicity: what are the options?
JE Knikman, H Gelderblom, JH Beijnen… - Clinical …, 2021 - Wiley Online Library
Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although
most often well tolerated, severe toxicity is encountered in~ 20–30% of the patients …
most often well tolerated, severe toxicity is encountered in~ 20–30% of the patients …
Genomics of rare genetic diseases—experiences from India
S Sivasubbu, V Scaria - Human genomics, 2019 - Springer
Home to a culturally heterogeneous population, India is also a melting pot of genetic
diversity. The population architecture characterized by multiple endogamous groups with …
diversity. The population architecture characterized by multiple endogamous groups with …
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
Y Zhou, VM Lauschke - Human Genetics, 2022 - Springer
Both safety and efficacy of medical treatment can vary depending on the ethnogeographic
background of the patient. One of the reasons underlying this variability is differences in …
background of the patient. One of the reasons underlying this variability is differences in …
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping
Fluoropyrimidines (FP; 5‐fluorouracil, capecitabine, and tegafur) are a commonly prescribed
class of antimetabolite chemotherapies, used for various solid organ malignancies in over 2 …
class of antimetabolite chemotherapies, used for various solid organ malignancies in over 2 …
Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
Pharmacogenomic screening can identify patients with gene variants that predispose them
to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of …
to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of …
[HTML][HTML] Fluorouracil therapy and DPYD genotype
L Dean, M Kane - 2021 - europepmc.org
Fluorouracil, or 5-flourouracil (5-FU), is a chemotherapy agent that belongs to the drug class
of fluoropyrimidines. When given as an intravenous (IV) solution, 5-FU is used in the …
of fluoropyrimidines. When given as an intravenous (IV) solution, 5-FU is used in the …
Population pharmacogenomics for precision public health in Colombia
While genomic approaches to precision medicine hold great promise, they remain
prohibitively expensive for developing countries. The precision public health paradigm …
prohibitively expensive for developing countries. The precision public health paradigm …
Cancer awareness, diagnosis and treatment needs in Mizoram, India: evidence from 18 years trends (2003–2020)
E Zomawia, Z Zami, A Vanlallawma… - The Lancet Regional …, 2023 - thelancet.com
Background Despite being the second least populated state, Mizoram exhibits the highest
incidence rate of cancer in India. Its inhabitants, constituting an endogamous and isolated …
incidence rate of cancer in India. Its inhabitants, constituting an endogamous and isolated …
Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness
Interethnic variability in drug response arises from genetic differences associated with drug
metabolism, action and transport. These genetic variations can affect drug efficacy as well as …
metabolism, action and transport. These genetic variations can affect drug efficacy as well as …
Challenges and solutions in patient treatment strategies for stage II colon cancer
S Fotheringham, GA Mozolowski… - Gastroenterology …, 2019 - academic.oup.com
Colorectal cancer remains one of the most common cancers worldwide and, despite
improvements in treatment options for late-stage metastatic cancer, there are still questions …
improvements in treatment options for late-stage metastatic cancer, there are still questions …